Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

18.22
+0.32011.79%
Volume:171.98K
Turnover:3.11M
Market Cap:2.38B
PE:10.31
High:18.24
Open:17.99
Low:17.89
Close:17.90
52wk High:22.24
52wk Low:14.34
Shares:130.62M
Float Shares:126.15M
Volume Ratio:0.40
T/O Rate:0.14%
Dividend:0.96
Dividend Rate:5.27%
EPS(TTM):1.77
EPS(LYR):1.05
ROE:8.78%
ROA:0.95%
PB:0.88
PE(LYR):17.30

Loading ...

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Benzinga
·
31 mins ago

Immunocore reports second quarter financial results and provides a business update

GlobeNewswire
·
Aug 07

Provident Bank Names Michael a. Perito Svp, Head of Corporate Strategy

THOMSON REUTERS
·
Aug 06

Provident Bank Names Michael A. Perito SVP, Head of Corporate Strategy

GlobeNewswire
·
Aug 06

Royalty Pharma Reports Second Quarter 2025 Results

GlobeNewswire
·
Aug 06

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 05

Akora Resources Raises Additional Funds to Drive Bekisopa Development

Small Caps
·
Aug 05

TMC Releases Two Economic Studies with Combined NPV of $23.6B and Declares World-First Nodule Reserves

GlobeNewswire
·
Aug 04

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

GlobeNewswire
·
Aug 01

Morella Corporation Challenges Wildcat Resources’ Tabba Tabba PFS Claims

TIPRANKS
·
Aug 01

Raymond James Lifts Price Target on Provident Financial Services to $22 From $21, Keeps Strong Buy Rating

MT Newswires Live
·
Aug 01

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

GlobeNewswire
·
Jul 31

Press Release: Quarterly Activities Report

Dow Jones
·
Jul 30

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

GlobeNewswire
·
Jul 30

MetalsTech Advances Sturec Gold Mine with Strategic Funding and PFS Progress

TIPRANKS
·
Jul 29

Provident Fincl Services Is Maintained at Buy by DA Davidson

Dow Jones
·
Jul 29

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

GlobeNewswire
·
Jul 28

Provident Financial price target raised to $24 from $22 at DA Davidson

TIPRANKS
·
Jul 28

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

GlobeNewswire
·
Jul 28

Press Release: DEFENSE METALS SETTLES DEBT WITH HATCH THROUGH EQUITY

Dow Jones
·
Jul 28